Search Results Project Details

ு Share ▼

Back to Search Results

Description







Sub-Projects



Publications



Patents



Clinical Studies



News and More



History



Similar Projects

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)

Project Number 5UM1AI069399-14 **Contact PI/Project Leader** CHARIYALERTSAK, **SUWAT Other Pls**

Awardee Organization CHIANG MAI UNIVERSITY



Abstract Text

DESCRIPTION (provided by the applicant): The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) Is the renamed renewal of "Chiang Mai University HIV/AIDS Clinical Trials Unit-Sirisanthana, Thira" (Grant# U01 Al 069399, Feb 2007-Jan 2014), which expands beyond the Chiang Mai University Research Institute for Health Sciences (CMU-RIHES) to add the experience and resources of another major HIV research institution: the Thai Red Cross AIDS Research Centre (TRC-ARC), affiliated with Chulalongkorn University. The aim of the THAI CTU Is to collaborate with five Clinical Research Networks established by NIAID, NIH under RFA-AI-12-001, -004, -008, -011, and -012, in coordinating and executing clinical research in Thailand and the neighboring region to expand knowledge and improve treatment and prevention of HIV and related Infectious diseases. It also aims to assist the CRNs In refining their research agendas to meet the needs, priorities, circumstances, and sensitivities of low- and middle-income countries in hosting research studies, so that findings are of utility fo preventing and treating HIV and related conditions both universally, as well as in the country of research. Located in the cities of Chiang Mai and Bangkok, Thailand, the THAI CTU is led by Co-Principal Investigators Suwat Chariyalertsak and Kiat Ruxrungtham, plus P. Phanuphak, T. Sirisanthana, K. Supparatpinyo, G.J.P.(F) van Griensven, V. Sirisanthan, A. Avihingsanon, T. Puthanakit, and K. Srithanaviboonchal. It is comprised of four Clinical Research Sites which will implement clinical and related HIV studies on maternal, pediatric, and adult therapeutics, on topical microbicides to prevent HIV transmission, on Integrated population-based prevention strategies, and on vaccines. After appropriate community and ethical approvals, such studies will be conducted on volunteers from populations with both high and usual risk for HIV, including those seeking voluntary counseling and testing or healthcare, men who have sex with men and transgender women, HIV-discordant couples, persons who inject drugs, pregnant, neonates, children, adolescents, blood donors, and persons from the general population. RELEVANCE: Enlightened prevention programs reduced HIV transmission in Thailand, a beachhead for the explosive arrival of HIV into Asia in the 1980s. However, new infections remain unacceptably frequent. Thai Institutions as RIHES and TRC-ARC provide infrastructure, population access, and indigenous scientific expertise and leadership for valuable clinical research of global, regional, and local application in controlling the epidemic.

Public Health Relevance Statement

RELEVANCE: Enlightened prevention programs reduced HIV transmission in Thailand, a beachhead for the explosive arrival of HIV into Asia in the 1980s. However, new infections remain unacceptably frequent. Thai Institutions as RIHES and TRC-ARC provide infrastructure, population access, and indigenous scientific expertise and leadership for valuable clinical research of global, regional, and local application in controlling the epidemic.

NIH Spending Category

Behavioral and Social Science Clinical Research

Clinical Trials and Supportive Activities

HIV/AIDS

Thank you for your feedback!

RePORT) RePORTER 11/29/21, 12:30 AM

> **Infectious Diseases Pediatric Pediatric AIDS Prevention**

Sexual and Gender Minorities (SGM/LGBT*) Vaccine Related **Topical Microbicides**

Women's Health

Project Terms

AIDS clinical trial group **AIDS** prevention AIDS/HIV problem

Adolescent **Acquired Immunodeficiency Syndrome** Acute Adult **Affect**

Centers for Disease Control and Prevention (U.S.) Behavioral Blood donor Asia

Child Clinic **Clinical Immunology** Childhood **Cities** Clinical

Clinical Virology Communicable Diseases Clinical Research Clinical Trials Unit

Communication **Communities Community Outreach Community Trial**

Community based prevention Counseling Country Couples Diagnosis

Drug Kinetics Epidemic Ethics Donor person Education **Environment**

Read More

Details

Contact PI/ Project Other Pls Program Official

Leader Name Name

RUXRUNGTHAM, KIAT GERMUGA, DONNA E Name

CHARIYALERTSAK, SUWAT Contact germugad@niaid.nih.gov

Title

Contact suwat@rihes.org

DIRECTOR

Organization

State Code Department Type Name **CHIANG MAI UNIVERSITY** Unavailable **Congressional District**

City **Organization Type CHIANG MAI** Unavailable Country

Other Information

THAILAND (TH)

FOA Administering Institutes or **Project Start** RFA-AI-12-018 Centers Date 2007

NATIONAL INSTITUTE OF **Study Section ALLERGY AND INFECTIOUS** ZAI1-BP-A(S3)

30-Project End **DISEASES** Date

November-**Award Notice DUNS Number** 2020 Date CFDA Code

660994984; Fiscal Year **Budget Start** 01-25-November-661744774 855 2020 2019 Date December-

2019

30-**Budget End** November-Date

2020

11/29/21, 12:30 AM RePORT) RePORTER

Total Funding Direct Costs Indirect Costs

\$2,034,744 \$1,961,158 \$73,586

Year Funding IC

2020 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES \$2,034,744

NIH Categorical Spending Click here for more information on NIH Categorical Spending

NIH Categorical Spending Click here for more information on NIH Categorical Spending		
Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$463	Pediatric AIDS
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$1,542	Women's Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$7,711	Behavioral and Social Science; Clinical Research; Clinical Trials and Supportive Activities; HIV/AIDS; Immunizatior Infectious Diseases; Pediatric; Prevention; Sexual and Gender Minorities (SGM/LGBT* Topical Microbicides Vaccine Related;
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$59,782	Pediatric AIDS
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$61,840	Pediatric AIDS
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$199,273	Women's Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$206,134	Women's Health

品 Sub Projects

No Sub Projects information available for 5UM1AI069399-14

Publications

11/29/21, 12:30 AM RePORT > RePORTER

No Publications available for 5UM1AI069399-14



No Patents information available for 5UM1AI069399-14

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5UM1AI069399-14

Clinical Studies

No Clinical Studies information available for 5UM1AI069399-14

News and More

Related News Releases

No news release information available for 5UM1AI069399-14

History

No Historical information available for 5UM1AI069399-14

Similar Projects

No Similar Projects information available for 5UM1AI069399-14